Blood Cancer Journal - Table of Contents alert Volume 3 March 2014

If you are unable to see the message below, click here to view.

Advertisement BD FACSCanto™ has 10-color capability.  Reliable performance, accuracy, and ease of use make the latest BD FACSCanto System a perfect 10 for today's busy clinical labs. Learn how you can achieve dependable outcomes while speeding workflow and reducing training requirements with clinical multi-color flow cytometry systems from BD Biosciences. bdbiosciences.com/go/canto   TABLE OF CONTENTS Volume 4, March 2014 In this issue Review Original Articles Erratum Sign up for e-alerts Web feed Advertisement Have you read these top articles from 2013 published in Blood Cancer Journal?  MEK inhibitors as a chemotherapeutic intervention in multiple myeloma   Lessons from next-generation sequencing analysis in hematological malignancies   The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics    Review Top Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature A Antar, H El Hajj, M Jabbour, I Khalifeh, F EL-Merhi, R Mahfouz and A Bazarbachi Blood Cancer J 2014 4: e190; 10.1038/bcj.2014.6 Abstract | Full Text Original Articles Top ProHNPs are specific markers of normal myelopoiesis F Emmertsen, A Glenthøj, J Sønderskov, P Kampmann, H Sengeløv and N Borregaard Blood Cancer J 2014 4: e193; 10.1038/bcj.2014.11 Abstract | Full Text 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies A O Gang, T M Frøsig, M K Brimnes, R Lyngaa, M B Treppendahl, K Grønbæk, I H Dufva, P thor Straten and S R Hadrup Blood Cancer J 2014 4: e197; 10.1038/bcj.2014.14 Abstract | Full Text CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo G Li, X Li, H Wu, X Yang, Y Zhang, L Chen, X Wu, L Cui, L Wu, J Luo and X Y Liu Blood Cancer J 2014 4: e194; 10.1038/bcj.2014.15 Abstract | Full Text Deregulated WNT signaling in childhood T-cell acute lymphoblastic leukemia O H Ng, Y Erbilgin, S Firtina, T Celkan, Z Karakas, G Aydogan, E Turkkan, Y Yildirmak, C Timur, E Zengin, J J M van Dongen, F J T Staal, U Ozbek and M Sayitoglu Blood Cancer J 2014 4: e192; 10.1038/bcj.2014.12 Abstract | Full Text Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin O E Olsen, K F Wader, K Misund, T K Våtsveen, T B Rø, A K Mylin, I Turesson, B F Størdal, S H Moen, T Standal, A Waage, A Sundan and T Holien Blood Cancer J 2014 4: e196; 10.1038/bcj.2014.16 Abstract | Full Text Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling X Sun, B Lu, B Hu, W Xiao, W Li and Z Huang Blood Cancer J 2014 4: e198; 10.1038/bcj.2014.18 Abstract | Full Text Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial M Tobiasson, I Dybedahl, M S Holm, M Karimi, L Brandefors, H Garelius, M Grövdal, I Högh-Dufva, K Grønbæk, M Jansson, C Marcher, L Nilsson, A O Kittang, A Porwit, L Saft, L Möllgård and E Hellström-Lindberg Blood Cancer J 2014 4: e189; 10.1038/bcj.2014.8 Abstract | Full Text Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients B A Walker, C P Wardell, A Brioli, E Boyle, M F Kaiser, D B Begum, N B Dahir, D C Johnson, F M Ross, F E Davies and G J Morgan Blood Cancer J 2014 4: e191; 10.1038/bcj.2014.13 Abstract | Full Text Erratum Top Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups L Riva, C Ronchini, M Bodini, F Lo-Coco, S Lavorgna, T Ottone, G Martinelli, I Iacobucci, C Tarella, A Cignetti, S Volorio, L Bernard, A Russo, G E M Melloni, L Luzi, M Alcalay, G I Dellino and P G Pelicci Blood Cancer J 2014 4: e195; 10.1038/bcj.2014.19 Full Text You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.